RVPH — REVIVA PHARMACEUTICALS HOLDINGS, INC.

—
OTC · Health Care · Pharmaceuticals · CIK 1742927 ·
Last close
$0.31
Market Cap
$4.02M
52W High
$15.40
52W Low
$0.26
ADV30
33,522
Next earnings
2026-11-16
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -2,432,518 -2,298,905 18,557,325 17,458,418 5,477,964
Jun 2026 0 — -2,617,543 -2,447,831 21,140,590 19,889,960 5,933,345
Mar 2026 0 — -3,271,952 -3,195,987 23,559,636 22,190,231 6,119,155
Dec 2025 0 — -3,559,041 -3,367,679 15,923,198 14,438,792 7,275,553

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,304,395
Investing CF
—
Financing CF
$26,830,641
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.25
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-189,781,770
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,003,997
Pretax Income TTM
$-13,010,570
Interest Exp TTM
$6,573
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -20,200,031 -19,864,902 15,923,198 7,275,553 8,647,645 -24,594,643
Dec 2024 0 -30,798,889 -29,918,802 15,503,088 14,690,516 812,572 -33,543,916
Dec 2023 0 -39,503,636 -39,260,837 23,700,388 17,981,672 5,718,716 -28,324,353
Dec 2022 0 -28,228,758 -28,261,442 18,923,675 10,529,429 8,394,246 -18,960,581

TTM Snapshot

Revenues TTM
$468,085
NetIncome TTM
$-13,022,270
OpCashFlow TTM
—
Assets (Latest)
$21,140,590
Forward EPS
$-0.85

Peers — same industry

TickerNameMarket CapLastDaily %
SILO Silo Pharma, Inc. $4.00M $1.71 —
XTLB XTL BIOPHARMACEUTICALS LTD $3.98M $1.62 —
IMNN Imunon, Inc. $3.97M $0.61 —
KPRX KIORA PHARMACEUTICALS INC $4.11M $0.93 —
TCRT Alaunos Therapeutics, Inc. $4.22M $1.66 —

News headlines (Yahoo Finance, 1h cache)

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
2026-06-23 12:00 · Yahoo
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
2026-04-23 12:00 · Yahoo
RVPH: First Quarter 2026 Results
2026-05-27 10:55 · Yahoo
Reviva Announces Letter to Shareholders
2026-04-15 12:00 · Yahoo
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-30 10:05 · Yahoo
RVPH: Shareholder Letter Introduces New IP
2026-04-20 09:30 · Yahoo
RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2
2026-04-01 12:35 · Yahoo
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
2026-04-21 02:46 · Yahoo
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:35 · Yahoo
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 20:29 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.